- Home
- YOSH vs HOTH Comparison
YOSH vs HOTH Comparison
Compare YOSH & HOTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YOSH
- HOTH
- Stock Information
- Founded
- YOSH 2016
- HOTH 2017
- Country
- YOSH United States
- HOTH United States
- Employees
- YOSH N/A
- HOTH N/A
- Industry
- YOSH Restaurants
- HOTH Biotechnology: Pharmaceutical Preparations
- Sector
- YOSH Consumer Discretionary
- HOTH Health Care
- Exchange
- YOSH Nasdaq
- HOTH Nasdaq
- Market Cap
- YOSH 4.5M
- HOTH 4.9M
- IPO Year
- YOSH 2022
- HOTH 2019
- Fundamental
- Price
- YOSH $3.49
- HOTH $1.50
- Analyst Decision
- YOSH
- HOTH Strong Buy
- Analyst Count
- YOSH 0
- HOTH 4
- Target Price
- YOSH N/A
- HOTH $4.75
- AVG Volume (30 Days)
- YOSH 22.1K
- HOTH 25.5M
- Earning Date
- YOSH 11-19-2024
- HOTH 11-12-2024
- Dividend Yield
- YOSH N/A
- HOTH N/A
- EPS Growth
- YOSH N/A
- HOTH N/A
- EPS
- YOSH N/A
- HOTH N/A
- Revenue
- YOSH $11,652,880.00
- HOTH N/A
- Revenue This Year
- YOSH N/A
- HOTH N/A
- Revenue Next Year
- YOSH N/A
- HOTH N/A
- P/E Ratio
- YOSH N/A
- HOTH N/A
- Revenue Growth
- YOSH 25.97
- HOTH N/A
- 52 Week Low
- YOSH $2.71
- HOTH $0.58
- 52 Week High
- YOSH $8.25
- HOTH $3.80
- Technical
- Relative Strength Index (RSI)
- YOSH 52.84
- HOTH 58.81
- Support Level
- YOSH $2.71
- HOTH $1.50
- Resistance Level
- YOSH $3.62
- HOTH $1.71
- Average True Range (ATR)
- YOSH 0.20
- HOTH 0.45
- MACD
- YOSH 0.07
- HOTH 0.04
- Stochastic Oscillator
- YOSH 85.79
- HOTH 25.54
About YOSH Yoshiharu Global Co.
Yoshiharu Global Co is a restaurant operator. The company has one reportable segment, consisting of operating its stores. Yoshiharu serves the perfect, ideal ramen, as well as offers customers a wide variety of sushi, bento menus, and other favorite Japanese cuisines. It owns and operates restaurant stores.
About HOTH Hoth Therapeutics Inc.
Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.